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1. Introduction
  Nocturnal frontal epilepsy (NFLE) is idiopathic partial epilepsy, 
mainly characterized by clusters of frequent transient motion 
nocturnal seizures. NFLE occurs mostly at or shortly before 
awakening after sleep, and rarely during the daytime. Neuroimaging 
and interictal electroencephalography (EEG) examinations show 
no abnormalities in NFLE patients, so they are often misdiagnosed 
as having sleep disorders. In 1994, Scheffer et al first reported 
NFLE pedigrees; they showed that there was autosomal dominant 
inheritance in the pedigrees, which they named autosomal dominant 
nocturnal frontal epilepsy (ADNFLE)[1]. In the clinic, sporadic cases 
of ADNFLE are more common, and only 25% of NFLE patients 
have a family history. Notably, sporadic cases and cases with a 
family history of NFLE have similar clinical and EEG features[2].
  Over the past decade, molecular genetics studies have demonstrated 
that neuronal nicotinic acetylcholine receptor (nAChR) is closely 
related to the pathogenesis of ADNFLE[2]. To date, the nAChR 毩
4, 毬2, and 毩2 subunits, encoded by the genes CHRNA4, CHRNB2, 
and CHRNA2, respectively, have been identified[3-5]. However, 
due to the high genetic heterogeneity of ADNFLE, mutations in 
the CHRNA4, CHRNB4, and CHRNA2 genes are only found in 
approximately 10% of ADNFLE patients. Therefore, it is speculated 
that genes encoding other nAChR subunits may be responsible for 
NFLE.
  In our previous studies, we could not detect mutations in 
CHRNA2, CHRNB2, or CHRNA4 in 215 Southern Han Chinese 
patients with sporadic NFLE[6,7]. In this study, we employed the 
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same subjects to screen mutations in the CHRNA7 gene, encoding 
the nAChR 毩7 subunit, in order to identify a new gene responsible 
for NFLE in the Chinese Han population.
2. Materials and methods
2.1. Subjects
  A total of 215 sporadic cases of NFLE were collected from 
Guangdong, Hunan, Jiangxi, and Sichuan between 2006 and 2012. 
All of them were Han Chinese, the male:female ratio was 1.2:1, 
and the average age of onset was (10.71依0.62) years old. A detailed 
questionnaire regarding patient history was completed, and physical 
examination, long-range video EEG, brain magnetic resonance 
imaging, and other tests were performed.
  All patients were diagnosed in strict accordance with the 
classification criteria for the diagnosis of epilepsy and epilepsy 
syndrome by the 2010 International League Against Epilepsy 
(ILAE)[8], At least 90% of the patients had clinical episodes during 
the night. The patients were diagnosed as having NFLE based 
on the clinical manifestations and laboratory examinations. The 
neurological examination was normal, and the family history was 
negative.
  As the control, 200 healthy Han Chinese were studied. All subjects 
or their legal guardians signed an informed consent form, and the 
protocol was approved by the Ethics Committee of Guangdong 
Provincial People’s Hospital.
2.2. DNA Extraction
  Blood samples (4 mL) were collected from 215 sporadic ADNFLE 
patients and 200 healthy controls and put into EDTA anticoagulant 
tubes. Genomic DNA was extracted using a DNA extraction kit 
(QIAampdna Kit, QIAGEN, Shanghai, China).
2.3. Polymerase Chain Reaction (PCR) 
  PCR was performed in a total volume of 25 毺L, containing 13.9 
毺L of ddH2O, 5 毺L of betaine, 2.5 毺L of 10伊 Buffer, 2 毺L of 
1伊dNTP, 0.3 毺L of Taq enzyme (50 U/毺L), 0.3 毺L of primers 
(50 M), and 1 毺L of genomic DNA (15 ng/毺L), on an ABI9700 
instrument (Applied Biosystems, USA). The primers for all exons of 
CHRNA7 were designed using Primer 3.0 online software with the 
following sequences: 
exon1 forward 5’ gacagccgagacgtggag 3’ and reverse 5’ 
tgagtggttgcgagtcattg 3’
exon 2 forward 5’ tgcttgtctgggctgcac 3’, and reverse 5’ 
tagcttggggccaactagag 3’
exon 3 forward 5’ attggaagtgcttggtgcat 3’, and reverse 5’ 
tcttgtgcatgtgttgagca 3’
exon 4 forward 5’ ttctctttggttttgcacttacc 3’, and reverse 5’ 
catatccagcatctctgtgaaa 3’
exon 5 forward 5’ ggcccctctcaaggtcttt 3’, and reverse 5’ 
gaagcaaagagctggtccac 3’
exon 6 forward 5’ tccatttgctctggactgtg 3’, and reverse 5’ 
caccggaaaggacagtgg 3’
exon 7 forward 5’ aggactgtgcttgtgtgtgg 3’, and reverse 5’ 
ccaggaaccctgatggagt 3’
exon 8 forward 5’ aatgcacacgcccatacata 3’, and reverse 5’ 
cagcaaatcatcaccttcca 3’.
  The cycling program was as follows: initial denaturation at 95 曟 
for 10 min; 38 cycles of denaturation at 94 曟 for 30 s, annealing 
at 60 曟 for 30 s, and extension at 72 曟 for 40 s; and then a final 
extension at 72 曟 for 10 min. PCR products were detected under 
UV light by 1.5% agarose gel electrophoresis with ethidium blue 
staining.
2.4. PCR product purification
  The PCR product (2毺L) was mixed with  5毺L of purification mix 
containing 4.71 毺L of ddH2O, 0.25 毺L of Exo栺, and 0.04 毺L of 
FaSAP; and the mixture was incubated at 37 曟 for 60 min and at 
80 曟 for 15 min.
2.5. Sequencing 
  Sequencing was performed in a 5-毺L system containing 2 毺L 
of purified PCR product, 2 毺L of forward or reverse sequencing 
primer (1.6 M), and 1 毺L of BigDye Terminator reaction solution 
(Applied Biosystems Company) on an ABI3730 sequencer. The 
cycling program was as follows: 96  曟 for 1 min; 28 cycles of 96 曟 
for 20 s, 50 曟 for 10 s, and 60 曟 for 3 min; and then 15 曟 for 10 
min. The sequencing results were analyzed using DNA Sequencing 
Analysis 5.1.1 software, with the GenBank sequence for the 
CHRNA7 gene as the standard.
3. Results
  We screened all exon sequences of CHRNA7 in the 215 sporadic 
NFLE patients and failed to detect any gene mutations. Instead, we 
found five different SNPs in sporadic cases, which were located on 
exons 5, 6, and 7 of the CHRNA7 gene (Table 1, Figure 1-5). Among 
them, c.690G>A and c.698A>G are known, while c.370G>A, 
c.654C>T, and c.497-498delTG were newly discovered SNPs. These 
SNPs were also found in some of the healthy controls.
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Table 1
SNPs of the CHRNA7 gene in sporadic ADNFLE patients 
Base change Exon  Amino acid change acidrs number
c.370G>A 5 Ala→Thr -
c.497_498delTG 6 Leu→Gln -
c.654C>T 7 Pro -
c.690G>A 7 Thr rs201822909
c.698A>G 7 Tyr→Cys rs142728508
Figure 1. Sequence of c.370G>A in the CHRNA7 gene of a sporadic 
ADNFLE patient.
 
Figure 2. Sequence of c.497_498delTG in the CHRNA7 gene of a sporadic 
ADNFLE patient.
 
Figure 3. Sequence of c.654C>T in the CHRNA7 gene of a sporadic 
ADNFLE patient.
 
Figure 4. Sequence of c.690A>G in the CHRNA7 gene of a sporadic 
ADNFLE patient.
 
Figure 5. Sequence of c.698G>A in the CHRNA7 gene of a sporadic 
ADNFLE patient.
4. Discussion
  ADNFLE is the first identified gene whose mutations are implicated 
in familial idiopathic partial epilepsy. A lot of studies have suggested 
that ADNFLE is highly correlated with the nAChR gene mutation, 
but there are racial and geographical differences due to significant 
genetic heterogeneity of the nAChR genes[2]. Because sporadic 
cases and familial cases of NFLE have a similar incidence, clinical 
presentation, EEG features, and treatment outcomes, sporadic cases 
are likely to have the same genetic causes as familial cases. However, 
the vast majority of nAChR gene mutations have been reported only 
in a small number of familial cases but rarely found in sporadic 
cases[9]. The molecular genetics of ADNFLE has mainly focused on 
the genes CHRNA4, CHRNB2, and CHRNA2, while genes encoding 
other nAChR subunits remain uncharacterized.
  nAChR is an important synaptic signaling ligand-gated ion 
channel protein, consisting of more than 10 subunits to form a 
receptor superfamily. 毩4毬2 and 毩7 are the main nAChR receptor 
subtypes distributed in the central nervous system[10]. Among the 
nAChR receptor subtypes, 毩7nAChR is a unique subtype that 
consists of five identical subunits, has a very high permeability for 
calcium ions, and regulates calcium activation and the release of 
the neurotransmitter acetylcholine[11]. The CHRNA7 gene, which 
encodes the 毩7 subunit, is located on chromosome 15q14. In the 
nervous system, 毩7nAChR is mainly distributed in the hippocampus, 
the medial and lateral geniculate nucleus, and the thalamic 
reticular nucleus, which are implicated in the pathophysiology 
of epilepsy[12]. In addition, 毩7nAChR is expressed in peripheral 
CD4+ T lymphocytes, bronchial epithelial cells, and macrophages. 
毩7nAChR regulates neuronal excitability to maintain normal 
behavioral responses, and participates in the release of neuropeptides 
and the inhibition of inflammation. The CHRNA7 gene has been 
implicated in a variety of neurological disorders such as epilepsy, 
Alzheimer’s disease, and schizophrenia[13]. Moreover, Helbig et al 
have proposed that CHRNA7 may contribute to the pathogenesis of 
idiopathic generalized epilepsy[14].
  In previous studies, we examined the mutations of the genes 
CHRNA4, CHRNB2, and CHRNA2 in 215 patients with sporadic 
NFLE, and we found no known mutations in these genes[6,7]. 
Zhi-Hong Chen et al./Asian Pacific Journal of Tropical Medicine (2015)330-333 333
Therefore, in this study, we focused on the CHRNA7 gene as a 
candidate gene. After sequencing all exons of the CHRNA7 gene 
in sporadic NFLE patients, we found no mutations but five SNPs 
in exons 5, 6, and 7. Two of them (c.690G>A and c.698A>G) 
are known SNPs, while the other three (c.370G>A, c.654C>T, 
and c.497-498delTG) are newly discovered SNPs. It has been 
reported that the “repeat 毩7nAChR” gene CHRFAM7A exists in 
peripheral lymphocytes[15]. However, Gault et al have found that 
in CHRFAM7A, a polymorphism (c.497-498delTG) could cause 
a reading frame shift, resulting in a stop codon in exon 6 and 
dysfunction of the truncated 毩7 subunit[16]. The CHRFAM7A 
polymorphism c.497-498delTG is likely to be a risk factor for 
idiopathic generalized epilepsy[17]. In this study, we found a deletion 
variant (c.497_498delTG) in the CHRNA7 gene in both patients 
and controls, indicating that it is a SNP but not a mutation. Further 
studies are necessary to understand whether the amino acid deletion 
variant has any impact on the transcription and/or function of the 
nAChR receptor, thus contributing to the pathogenesis of ADNFLE.
  In summary, in the present study, we found no mutations but five 
SNPs in the CHRNA7 gene in the Southern Han Chinese population. 
We speculate that the CHRNA7 gene is probably not the major gene 
responsible for NFLE in this population. Notably, we identifed three 
new SNPs (c.370G>A, c.654C>T, and c.497_498delTG), providing 
candidate sites for subsequent gene mapping and gene function 
studies on epilepsy.
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